In agreement with our ovarian carcinoma data (Figure 3B and Table 2), CD70 has recently been reported as a potential cisplatin resistance marker in ovarian cancer using proteomic methods (Aggarwal et al, 2009). This evidence concerns the gene CD70 and ovarian carcinoma.